Jama Oncology
Overview
JAMA Oncology is a prestigious peer-reviewed medical journal that focuses on all aspects of cancer research and clinical practice. It publishes high-quality original research, reviews, and commentaries, covering topics such as cancer biology, prevention, diagnosis, treatment, and survivorship. With its rigorous editorial process and wide readership, JAMA Oncology serves as a vital resource for oncologists, researchers, and healthcare professionals seeking the latest advancements in the field.
Details
Details
Abbr.
JAMA Oncol
Publisher
American Medical Association
Start
2015
End
Continuing
Frequency
Monthly
p-ISSN
2374-2437
e-ISSN
2374-2445
Country
United States
Language
English
Specialty
Oncology
Metrics
Metrics
h-index / Ranks: 1033
173
SJR / Ranks: 116
7843
CiteScore / Ranks: 77
44.30
JIF / Ranks: 88
28.4
Recent Articles
1.
Tilki D, Chen M, Wu J, Huland H, Graefen M, Trock B, et al.
JAMA Oncol
. 2025 Mar;
PMID: 40080000
Importance: Whether the conventional 1.5-month to 2.0-month time interval following radical prostatectomy (RP) for prostate cancer (PC) is sufficient to accurately document a persistent prostate-specific antigen (PSA) remains unanswered. Objective:...
2.
Adjuvant Chemoradiotherapy vs Radiotherapy Alone for Patients With Intermediate-Risk Cervical Cancer
Agusti N, Viveros-Carreno D, Wu C, Wilke R, Kanbergs A, Barajas K, et al.
JAMA Oncol
. 2025 Mar;
PMID: 40079948
Importance: Optimal adjuvant treatment for patients with intermediate-risk cervical cancer remains controversial, and the benefit of adding chemotherapy to radiotherapy in this population is uncertain. Objective: To evaluate whether adjuvant...
3.
4.
5.
6.
7.
8.
9.
Rosenberg A, Juloori A, Jelinek M, Agrawal N, Cursio J, Cipriani N, et al.
JAMA Oncol
. 2025 Mar;
PMID: 40048190
Importance: Neoadjuvant immunotherapy in human papillomavirus (HPV)-negative locoregionally advanced (LA) head and neck squamous cell carcinoma (HNSCC) appears promising, yet its role in nonsurgical treatment for head and neck cancer...
10.
Michel L, Schwarz D, Romar P, Feisst M, Hamberger D, Priester A, et al.
JAMA Oncol
. 2025 Mar;
PMID: 40048176
Importance: Chemotherapy-induced peripheral neuropathy (CIPN) is a common, dose-limiting adverse effect of taxane-based chemotherapies. Currently, there is no established strategy for prevention or treatment. Objective: To compare the effectiveness of...